# DGX earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/DGX) · [Earnings tab](https://www.lopjlb.com/stock/DGX?tab=earnings) Updated: 2026-09-14T01:53:24 Quarters analyzed: 8 ## Cross-quarter narrative Across eight quarterly calls, Quest Diagnostics moved from vague guidance and modest tone in early 2024 to increasingly upbeat management commentary by 2026, highlighted by consecutive revenue growth double‑digits and raised guidance. Demand stayed robust across physician, hospital and consumer channels, with clinical innovation (advanced diagnostics, MRD, Alzheimer’s tests) and partnership volume (Fresenius, Corewell) driving growth. Margins improved modestly, aided by cost‑saving programs (Invigorate) and automation, though wage inflation and weather‑related volume dips occasionally pressured profitability. Capital deployment shifted from acquisition integration in 2024‑25 to large‑scale technology spend on Project Nova and AI tools, while capex remained around $500‑$550 M annually. Regulatory uncertainty around PAMA reforms and LDT rules persisted, and the timing of Project Nova investments slipped, creating short‑term margin headwinds. Overall, the company’s narrative evolved toward confidence in demand and execution, tempered by recurring external risks and the need to manage mix‑related revenue per requisition declines. ## Latest CallCard · Q2 Quest Diagnostics Q2 2026: revenue +10.2% YoY, adj EPS +19%, raised FY guidance; broad clinical demand, Corewell/Fresenius drive volume; Haystack MRD milestones, Alzheimer's testing high double-digit growth; PAMA/RESULTS Act uncertainty. **Guidance:** raised — Raised FY2026 revenue to $11.95-12.05B (8.3-9.2% growth) and adjusted EPS to $11.05-11.25; operating margin expected to expand. **Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3 Management highlighted strong execution across channels, raised full-year guidance again, and emphasized strategic milestones in oncology and Alzheimer's testing. ### Demand visibility Broad-based clinical demand across physician, hospital, consumer channels with strong volume growth. Organic volume +13% YoY (excl. Corewell/Fresenius +4.1%); physician channel high single-digit revenue growth; hospital channel double-digit growth driven by Corewell Co-Lab; consumer health robust growth; advanced diagnostics in 5 clinical areas double-digit growth; Alzheimer's testing high double-digit growth. ### Margins / costs Adjusted operating margin 16.5% vs 16.9% prior year; impacted by Project Nova investments, Corewell ramp, deferred comp. Adjusted operating income $502M (16.5% margin) vs $466M (16.9%); 70bps reduction from Project Nova, Corewell Co-Lab lower margin ramp, higher supplemental deferred comp; Invigorate program on track for 3% annual cost savings; wage increases offsetting productivity gains. ### Capital allocation Cash from operations $875M YTD; capex ~$550M FY; share count slightly below 2025; no M&A in guidance. Cash from operations $875M YTD vs $858M prior year; FY capex ~$550M; share count expected slightly below 2025; interest expense consistent with 2025; guidance excludes prospective M&A contributions. ### Milestones - **Haystack MRD NY State approval** [delivered]: Approved by New York State, enabling commercial efforts in all 50 states. - **Haystack MRD Flatiron Health Onco EMR integration** [delivered]: Largest reference lab to extend access via Flatiron's Molecular Profiling platform. - **Haystack MRD pilot with American Oncology Network** [on_track]: Pilot begun, plan to roll out to Flatiron's 4,700 clinicians nationwide later this year. - **Genius digital diagnostic system expansion** [delivered]: Installed in 2 more locations following successful implementations at about half a dozen sites. - **Genius digital diagnostic system further rollout** [on_track]: Plan to extend solution to other sites later this year. - **IntelliDraw web-based specimen collection tool** [delivered]: Launched to guide clinical staff through specimen collection, improving quality and service experience. - **AI tool for patient service centers** [on_track]: Implementation planned this year to cut time to track and order supplies. - **Invigorate cost savings program** [on_track]: On track to deliver 3% annual cost savings and productivity improvements. ### Fears / risks - **PAMA/RESULTS Act policy uncertainty**: Three possible outcomes: CMS data collection results (Sept/Oct), RESULTS Act passage (rates flat '27-'28, new rates 2029, 5% cap), or another delay (6th delay). - **Partial Alzheimer's biomarker reimbursement**: Elevance covers pTau217 but not AB-42/40; combined panel with algorithmic interpretation is selling well but full dual-biomarker coverage not yet universal. - **Hospital sector financial pressures**: Hospitals contending with workforce, financial and other pressures; could affect Co-Lab pipeline and reference testing volumes. - **Corewell/Fresenius mix impact on revenue per requisition**: Total revenue per requisition down 2.8% YoY due to business mix; adjusting for mix, up 2.9%. - **Project Nova investment margin pressure**: Project Nova expenses unchanged for full year but increased spend anticipated in H2 vs prior expectations. - **Higher fuel costs**: Higher fuel costs expected in H2 2026 versus prior expectations. - **MRD competitive landscape**: Haystack MRD competing on clinical evidence and assay sensitivity/specificity; ongoing studies in breast and lung needed. - **Volume dependence on large partnerships**: Corewell and Fresenius contributed 9% of volume in quarter; organic volume ex-partnerships grew 4.1%. ### Key quotes > “Our strong performance in the second quarter demonstrates focused execution of our strategy to connect people and providers to innovative testing and actionable insights that illuminate past or better health.” > “With our strong first half performance and continued momentum, we are raising our full year revenue and EPS estimates.” > “We're not seeing any slowdown in our hospital business, whether it's Co-Lab or reference.” > “It is growing in the high, high double digits.” > “We're never going to give up on that because we think that is the best approach to figuring out what the actual market rates are for laboratory testing.” — James Davis ## Quarter one-liners - **2026 Q2:** Quest Diagnostics Q2 2026: revenue +10.2% YoY, adj EPS +19%, raised FY guidance; broad clinical demand, Corewell/Fresenius drive volume; Haystack MRD milestones, Alzheimer's testing high double-digit growth; PAMA/RESULTS Act uncertainty. - **2026 Q1:** Quest Diagnostics raises 2026 guidance after Q1 revenue +9.2% (organic +9%), adjusted EPS +13%, driven by broad-based clinical innovation demand, Fresenius/Corewell contributions, AI productivity gains, and consumer health growth. - **2025 Q4:** Quest Diagnostics reported double‑digit revenue and EPS growth in 2025, highlighted strong demand across physician, hospital and consumer channels, and gave 2026 guidance of 6‑7% revenue growth despite weather headwinds and ongoing regulatory and partnership integration challenges. - **2025 Q3:** Quest Diagnostics reported 13% revenue growth, raised full‑year 2025 guidance and highlighted strong demand across clinical, consumer and hospital channels while flagging PAMA reform risk and timing of Project Nova investments. - **2025 Q2:** Quest Diagnostics raised 2025 guidance after Q2 beat with 15.2% revenue growth (5.2% organic), driven by acquisitions, advanced diagnostics, and utilization; minimal policy impact expected; automation and Project Nova investments underway. - **2025 Q1:** — - **2024 Q4:** Quest Diagnostics reported ~15% Q4 revenue growth, strong acquisition integration and automation gains, and reaffirmed 2025 guidance with confidence in demand and margin expansion. - **2024 Q3:** — ## Theme arcs - **Revenue growth** (improving): Consistent double‑digit YoY increases and raised guidance from 2025 Q2 through 2026 Q2. - **Demand across channels** (stable): Strong physician, hospital and consumer demand reported in every call. - **Margin expansion** (improving): Operating margin rose from 16.6% to 16.9% then modestly to 16.5% despite cost pressures. - **Automation & AI productivity** (improving): Automation solutions, AI companion and Project Nova progressed, offsetting some wage inflation. - **Regulatory risk (PAMA/LDT)** (deteriorating): Repeated warnings about potential rate cuts and compliance costs. - **Weather impact** (deteriorating): Severe weather events in Q4 2025 and Jan 2026 trimmed volume and margins. - **Capital allocation** (stable): Capex steady around $500‑$550 M, focused on technology and partnership integration. - **Partnership mix impact** (deteriorating): Fresenius and Corewell mix lowered revenue per requisition, pressuring margins. - **Project Nova timing** (deteriorating): Investment delayed to Q4 2025 and Q4 2026, creating short‑term margin compression. - **Alzheimer’s test reimbursement** (new): Partial coverage for pTau217 introduced in 2026 Q2, full dual‑biomarker reimbursement pending. ## Guidance path 2024 Q3:vague → 2024 Q4:maintained → 2025 Q1:vague → 2025 Q2:raised → 2025 Q3:raised → 2025 Q4:maintained → 2026 Q1:raised → 2026 Q2:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/DGX`